Fumaric Acid Esters Stimulate Astrocytic VEGF Expression through HIF-1α and Nrf2

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Wiesner, Diana ^a   Merdian, Irma ^a   Lewerenz, Jan ^a   Ludolph, Albert C ^a   Dupuis, Luc ^b,c   Witting, Anke ^a  

^a UNIVERSITY OF ULM   (Germany)

^b INSERM   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; MALE; MICROGLIA; MOUSE; NERVE CELL; NONHUMAN; OLIGODENDROGLIA; PROTEIN SECRETION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ASTROCYTES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FUMARATES; GENE EXPRESSION REGULATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, TRANSGENIC; MUTATION; NF-E2-RELATED FACTOR 2; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884831484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076670     Document Type: Article

References (40)

1. Arbiser JL, (2011) Fumarate esters as angiogenesis inhibitors: key to action in psoriasis? J Invest Dermatol 131: 1189-1191. doi:10.1038/jid.2011.45. PubMed: 21566578.
2. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, et al. (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367: 1098-1107. doi:10.1056/NEJMoa1114287. PubMed: 22992073.
3. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, et al. (2012) Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 9: 163. doi:10.1186/1742-2094-9-163. PubMed: 22769044.
4. Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, et al. (2012) Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappa B (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem 287: 28017-28026. doi:10.1074/jbc.M112.383380. PubMed: 22733812.
5. Lin SX, Lisi L, Dello Russo C, Polak PE, Sharp A, et al. (2011) The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN. New Eur 3.
6. Ashrafian H, Czibik G, Bellahcene M, Aksentijević D, Smith AC, et al. (2012) Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab 15: 361-371. doi:10.1016/j.cmet.2012.01.017. PubMed: 22405071.
7. Oh CJ, Kim JY, Choi YK, Kim HJ, Jeong JY, et al. (2012) Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling. PLOS ONE 7: e45870. doi:10.1371/journal.pone.0045870. PubMed: 23056222.
8. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, et al. (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 341: 274-284. doi:10.1124/jpet.111.190132. PubMed: 22267202.
9. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134: 678-692. doi:10.1093/brain/awq386. PubMed: 21354971.
10. Koivunen P, Hirsilä M, Remes AM, Hassinen IE, Kivirikko KI, et al. (2007) Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 282: 4524-4532. PubMed: 17182618.
11. Serra-Pérez A, Planas AM, Núñez-O'Mara A, Berra E, García-Villoria J, et al. (2010) Extended ischemia prevents HIF1alpha degradation at reoxygenation by impairing prolyl-hydroxylation: role of Krebs cycle metabolites. J Biol Chem 285: 18217-18224. doi:10.1074/jbc.M110.101048. PubMed: 20368331.
12. Dungwa JV, Hunt LP, Ramani P, (2011) Overexpression of carbonic anhydrase and HIF-1alpha in Wilms tumours. BMC Cancer 11: 390. doi:10.1186/1471-2407-11-390. PubMed: 21910893.
13. Semenza GL, (2011) Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol 76: 347-353. doi:10.1101/sqb.2011.76.010678. PubMed: 21785006.
14. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, et al. (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34: 383-394. doi:10.1038/ng1211. PubMed: 12847526.
15. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, et al. (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28: 131-138. doi:10.1038/88842. PubMed: 11381259.
16. Moreau C, Gosset P, Kluza J, Brunaud-Danel V, Lassalle P, et al. (2011) Deregulation of the hypoxia inducible factor-1alpha pathway in monocytes from sporadic amyotrophic lateral sclerosis patients. Neuroscience 172: 110-117. doi:10.1016/j.neuroscience.2010.10.040. PubMed: 20977930.
17. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429: 413-417. doi:10.1038/nature02544. PubMed: 15164063.
18. Loureiro RM, D'Amore PA, (2005) Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev 16: 77-89. doi:10.1016/j.cytogfr.2005.01.005. PubMed: 15733833.
19. Chen J, Imanaka N, Griffin JD, (2010) Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer 102: 351-360. doi:10.1038/sj.bjc.6605486. PubMed: 20010940.
20. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS, (2008) PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 105: 2622-2627. doi:10.1073/pnas.0706790105. PubMed: 18268343.
21. Fan W, Tang Z, Chen D, Moughon D, Ding X, et al. (2010) Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy 6: 614-621. doi:10.4161/auto.6.5.12189. PubMed: 20495340.
22. Alam J, Killeen E, Gong P, Naquin R, Hu B, et al. (2003) Heme activates the heme oxygenase-1 gene in renal epithelial cells by stabilizing Nrf2. Am J Physiol Renal Physiol 284: F743-F752. PubMed: 12453873.
23. Lee JM, Anderson PC, Padgitt JK, Hanson JM, Waters CM, et al. (2003) Nrf2, not the estrogen receptor, mediates catechol estrogen-induced activation of the antioxidant responsive element. Biochim Biophys Acta 1629: 92-101. doi:10.1016/j.bbaexp.2003.08.006. PubMed: 14522084.
24. Suswam E, Li Y, Zhang X, Gillespie GY, Li X, et al. (2008) Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res 68: 674-682. doi:10.1158/0008-5472.CAN-07-2751. PubMed: 18245466.
25. Anderson P, (2008) Post-transcriptional control of cytokine production. Nat Immunol 9: 353-359. doi:10.1038/ni1584. PubMed: 18349815.
26. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, et al. (2001) Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61: 947-954. doi:10.1016/S0006-2952(01)00564-0. PubMed: 11286986.
27. Yan J, Zhou B, Taheri S, Shi H, (2011) Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic stroke. PLOS ONE 6: e27798. doi:10.1371/journal.pone.0027798. PubMed: 22110762.
28. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, et al. (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525. doi:10.1093/jnci/95.7.516. PubMed: 12671019.
29. Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, et al. (2007) YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26: 3941-3951. doi:10.1038/sj.onc.1210169. PubMed: 17213816.
30. Kim HL, Yeo EJ, Chun YS, Park JW, (2006) A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. Int J Oncol 29: 255-260. PubMed: 16773207.
31. Nagara Y, Tateishi T, Yamasaki R, Hayashi S, Kawamura M, et al. (2013) Impaired Cytoplasmic-Nuclear Transport of Hypoxia-Inducible Factor-1alpha in Amyotrophic Lateral Sclerosis. Brain Pathol.
32. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, et al. (2010) Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 133: 2248-2263. doi:10.1093/brain/awq179. PubMed: 20826430.
33. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, et al. (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLOS ONE 6: e16172. doi:10.1371/journal.pone.0016172. PubMed: 21297955.
34. Bolaños JP, Almeida A, Moncada S, (2010) Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci 35: 145-149. doi:10.1016/j.tibs.2009.10.006. PubMed: 20006513.
35. Ferger AI, Campanelli L, Reimer V, Muth KN, Merdian I, et al. (2010) Effects of mitochondrial dysfunction on the immunological properties of microglia. J Neuroinflammation 7: 45. doi:10.1186/1742-2094-7-45. PubMed: 20701773.
36. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, et al. (2008) HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451: 1008-1012. doi:10.1038/nature06613. PubMed: 18288196.
37. Vangeison G, Carr D, Federoff HJ, Rempe DA, (2008) The good, the bad, and the cell type-specific roles of hypoxia inducible factor-1 alpha in neurons and astrocytes. J Neurosci 28: 1988-1993. doi:10.1523/JNEUROSCI.5323-07.2008. PubMed: 18287515.
38. Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, et al. (2012) Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 122: 2454-2468. doi:10.1172/JCI60842. PubMed: 22653056.
39. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, et al. (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8: 85-92. doi:10.1038/nn1360. PubMed: 15568021.
40. Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, et al. (2006) Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg, Psychiatry 77: 255-257. doi:10.1136/jnnp.2005.070904. PubMed: 16421133.